SUSTAINABLE DEVELOPMENT
Innovate. Sustain. Transform.
Save up to 30% on top Physical Sciences & Engineering titles!
Pathophysiology, Pharmacology and Biochemistry of Dyskinesia
- 1st Edition, Volume 98 - September 7, 2011
- Editors: Jonathan Brotchie, Erwan Bezard, Peter Jenner
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 1 6 4 3 5 - 1
- Hardback ISBN:9 7 8 - 0 - 1 2 - 3 8 1 3 2 8 - 2
- eBook ISBN:9 7 8 - 0 - 1 2 - 3 8 1 3 2 9 - 9
Published since 1959, International Review of Neurobiology is a well-known series appealing to neuroscientists, clinicians, psychologists, physiologists, and pharmacologists. Le… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quotePublished since 1959, International Review of Neurobiology is a well-known series appealing to neuroscientists, clinicians, psychologists, physiologists, and pharmacologists. Led by an internationally renowned editorial board, this important serial publishes both eclectic volumes made up of timely reviews and thematic volumes that focus on recent progress in a specific area of neurobiology research. This volume reviews existing theories and current research surrounding the movement disorder Dyskinesia.
- Leading authors review state-of-the-art in their field of investigation and provide their views and perspectives for future research
- Chapters are extensively referenced to provide readers with a comprehensive list of resources on the topics covered
- All chapters include comprehensive background information and are written in a clear form that is also accessible to the non-specialist
Neuroscientists, neurologists, psychologists
Contributors
Preface
An Introduction to Dyskinesia—The Clinical Spectrum
I Introduction
II Akathisia
III Ballism
IV Chorea
V Dystonia
VI Jumpy Stumps
VII Levodopa-Induced Dyskinesias
VIII Assessment of Dyskinesia
IX Moving Toes and Moving Fingers
X Myoclonus
XI Myokymia
XII Myorhythmia
XIII Stereotypy
XIV Tardive dyskinesia
XV Tics
XVI Tremor
XVII Conclusion
L-Dopa-Induced Dyskinesia—Clinical Presentation, Genetics, and Treatment
I Introduction
II Historical Aspects
III Epidemiology
IV Risk Factors
V Genetics of Dyskinesia
VI Classification
VII Clinical Characteristics
VIII Treatment
Experimental Models of L-DOPA-Induced Dyskinesia
I Historical Development of a Model of L-DOPA-Induced Dyskinesia
II MPTP-Lesioned Primate Model of L-DOPA-Induced Dyskinesia
III Unilateral 6-OHDA Lesioned Rodent Model of L-DOPA-Induced Dyskinesia
IV Critique of Toxin-Based Models of L-DOPA-Induced Dyskinesia
V Alternative Models of L-DOPA-Induced Dyskinesia
VI Future Modeling of L-DOPA-Induced Dyskinesia
VII Conclusions
Molecular Mechanisms of L-DOPA-Induced Dyskinesia
I Introduction
II Basal Ganglia and Medium Spiny Neurons
III LID and Hyperactivity of D1R/cAMP Signaling
IV Increased ERK Signaling in LID: Transcriptional and Translational Changes
V Glutamate NMDA Receptors and LID
VI mGluR5
VII Controlling Dyskinesia by Acting on the MSNs of the Indirect Pathway
VIII Cannabinoid CB1 Receptors
IX Pre-Synaptic Mechanisms: Serotonin Receptors
X Conclusions
New Approaches to Therapy
I Introduction
II Factors that Control the Priming and Expression of LID
III Modifying LID Through Dopaminergic Approaches
IV Nondopaminergic Approaches to LID
V Conclusions
Surgical Approach to L-Dopa-Induced Dyskinesias
I Introduction
II Brief Overview of LID
III Surgical Treatment of LID: Efficacy and Mechanisms of Action by Target
IV Surgical Approach to the Patient With LID
V Conclusion
Clinical and Experimental Experiences of Graft-Induced Dyskinesia
I Introduction
II Transplantation for Parkinson’s Disease
III The Clinical Phenomena of GID
IV Animal Models of GID
V Understanding the Cause of GID
VI Strategies for Dealing with GID
VII Final Considerations
Tardive Dyskinesia: Clinical Presentation and Treatment
I Introduction
II Clinical Features
III Differential Diagnosis
IV Pathophysiology
V Tardive Dyskinesia Treatments
VI Prevention and Treatment of Tardive Dyskinesia in Clinical Practice
VII Conclusion
Epidemiology and Risk Factors for (Tardive) Dyskinesia
I Introduction
II Spontaneous Dyskinesia in Psychiatry
III Discussion
IV Conclusion
Genetics of Tardive Dyskinesia
I Introduction
II Genes Involved in Pharmacokinetics
III Genes Involved in Pharmacodynamics
IV Oxidative-Stress-Related Genes
V Other Genes Reported to be Associated with TD
VI The Genome-Wide Association Approach
VII Future Research: Copy-number Variations and Epigenetics
VIII TD as a Phenotype
IX Conclusion
Animal Models of Tardive Dyskinesia
I Introduction
II Limitations
III Conclusion
Surgery for Tardive Dyskinesia
I Introduction
II Lesioning Surgery
III Deep Brain Stimulation
IV Conclusion
Huntington’s Disease: Clinical Presentation and Treatment
I Clinical Presentation and Genetics
II The Clinical Phenotype and its Management
III The Atypical Phenotype, including Juvenile Huntington’s Disease
IV Advanced Disease and End of Life Issues
V Looking to the Future: Research into New Treatments for Huntington’s Disease
VI Conclusions
Genetics and Neuropathology of Huntington’s Disease
I Introduction
II The HD Gene
III Normal CAG Repeat Length
IV CAG Repeat Length and Disease Onset and Progression
V CAG Repeat Instability
VI Genetic Modifiers of CAG Repeat Instability
VII Genetic Modifiers of HD Age-of-Onset
VIII HD: A True Dominant Gain-of-Function Disorder?
IX Expression of Huntingtin in Normal and HD Human brain
X HD Brain Pathology and the Vonsattel Grading System
XI Basal Ganglia Pathology in HD
XII Other Telencephalic Areas in HD
XIII Brainstem Areas in HD
XIV HD and Neurogenesis
XV Neuroinflammatory Neuropathology in HD
Pathogenic Mechanisms in Huntington’s Disease
I Introduction
II The HTT Gene Product
III The Mutant Htt Protein and its Downstream Effects
IV Conclusions
Experimental Models of HD and Reflection on Therapeutic Strategies
I Introduction
II Mouse Models of HD
III Methodological Considerations for Mouse Therapeutic Trials
IV Existing Clinical Management
V Mechanisms of Cell Death and Potential Therapeutic Targets in HD
VI Conclusion
Cell-Based Treatments for Huntington’s Disease
I Introduction
II Present Status
III Future Developments
IV Conclusion
Clinical Phenomenology of Dystonia
I Historical Review
II Definition and Classification
III Clinical Features in Different Subtypes of Focal and Segmental Dystonia
IV Neuropsychiatric Features of Dystonia
V Conclusions
Genetics and Pharmacological Treatment of Dystonia
I Primary Torsion Dystonia
II Dystonia-Plus Syndromes without Brain Degeneration
III Dystonia as a Feature of Degenerative Genetic Syndromes
IV Treatment of Dystonia
Experimental Models of Dystonia
I Introduction
II Models of Genetic Engineering
III Spontaneous Mutants
IV Pharmacological and Neural Lesion Models
V Conclusions
Surgical Treatment of Dystonia
I Background
II Classification
III Medical Treatment of Dystonia
IV Surgical Treatment of Dystonia
V Deep Brain Stimulation (DBS) for Dystonia
VI DBS for Dystonia – Clinical Overview
VII Conclusion
Uncited
Index
Contents of Recent Volumes
- No. of pages: 664
- Language: English
- Edition: 1
- Volume: 98
- Published: September 7, 2011
- Imprint: Academic Press
- Paperback ISBN: 9780323164351
- Hardback ISBN: 9780123813282
- eBook ISBN: 9780123813299
PJ
Peter Jenner
Professor Peter Jenner is a specialist in preclinical aspects of neurodegenerative diseases, notably Parkinson’s disease. He has spent the major part of his career at King’s College London where he was Head of Pharmacology for 14 years before returning to his research roots and subsequently becoming Emeritus Professor of Pharmacology. Peter has expertise in drug metabolism and pharmacokinetics but neuropharmacology based on functional models of neurodegenerative diseases has formed the major focus of his work. Peter holds a BPharm, PhD and DSc degree from the University of London. He has published well over 1000 articles with more than 700 peer reviewed papers. He is a Fellow of the Royal Pharmaceutical Society, the British Pharmacological Society, the Royal Society of Medicine and of King’s College London. Peter was recently honoured with a Doctor Honoris Causa degree from Carol Davila University of Medicine and Pharmacy, Bucharest and made an Honorary Fellow of The British Pharmacological Society for his contribution to research in to movement disorders.
Peter has worked closely with the pharmaceutical industry for many years and acts as an adviser and consultant to both major pharma and biotech companies. He has a wide knowledge of the drug discovery and drug development process and has been involved from molecule synthesis through to drug registration for use in man. Peter was the Founder, Director and Chief Scientific Officer of Proximagen, a biotech focussed on the treatment and cure of neurodegenerative diseases that was listed on AIMs and subsequently purchased by a US based healthcare company. He is a regular speaker at international meetings and also takes time to speak at Parkinson’s disease patient-carer groups across the UK.
Affiliations and expertise
Emeritus Professor of Pharmacology, Institute of Pharmaceutical Sciences, King’s College London, London, UKRead Pathophysiology, Pharmacology and Biochemistry of Dyskinesia on ScienceDirect